These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19860043)

  • 1. Information for patients. HER2: what you need to know.
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):48a-48b. PubMed ID: 19860043
    [No Abstract]   [Full Text] [Related]  

  • 2. Inconsistency of HER2 test raises questions.
    Tuma RS
    J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788
    [No Abstract]   [Full Text] [Related]  

  • 3. Saving lives with accurate HER2 testing.
    Ross JS
    Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
    [No Abstract]   [Full Text] [Related]  

  • 4. Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):48a-48b. PubMed ID: 19856610
    [No Abstract]   [Full Text] [Related]  

  • 5. HER2 testing and correlation with efficacy of trastuzumab therapy.
    Konecny G; Slamon DJ
    Oncology (Williston Park); 2002 Nov; 16(11):1576, 1578. PubMed ID: 12469932
    [No Abstract]   [Full Text] [Related]  

  • 6. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of HER2 testing in the management of breast cancer.
    Ravdin P
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
    Ross JS
    Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
    Bult P; Tjan-Heijnen VC; van Krieken H
    Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
    [No Abstract]   [Full Text] [Related]  

  • 10. Focus on ERBB2.
    Benusiglio PR
    Pharmacogenomics; 2008 Jul; 9(7):825-8. PubMed ID: 18597646
    [No Abstract]   [Full Text] [Related]  

  • 11. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 12. [ERBB2/HER2: from molecular to clinical oncology].
    Khanson KP; Imianitov EN
    Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
    [No Abstract]   [Full Text] [Related]  

  • 13. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 14. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Schmidt C
    J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
    [No Abstract]   [Full Text] [Related]  

  • 15. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
    Eidtmann H
    Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in HER2-positive breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):98-100. PubMed ID: 18347559
    [No Abstract]   [Full Text] [Related]  

  • 17. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
    Aoyama K; Kamio T; Nishikawa T; Kameoka S
    Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human epidermal growth factor receptor 2 testing: where are we?
    De P; Smith BR; Leyland-Jones B
    J Clin Oncol; 2010 Oct; 28(28):4289-92. PubMed ID: 20697080
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.